Prellis Biologics Tech Stack
Lymph node organoid platform for antibody discovery and immunogenicity screening
Prellis Biologics operates a wet-lab and computational platform (EXIS™) centered on engineered lymph node organoids for high-throughput antibody discovery and immunogenicity assessment. The hiring mix is research-heavy (18 roles) with emerging engineering and data functions, suggesting they're scaling both wet-lab throughput and computational infrastructure to move from manual screening into automation. Active projects span organoid engineering, high-throughput expression, and liquid-handling automation—paired with flagged pain points around expression bottlenecks and data governance—indicating they're hitting the scaling wall that typically forces biotech platforms toward operational maturity.
Tech Stack 36 technologies
What Prellis Biologics Is Building
◆Challenges
- High-throughput expression capabilities
- Bottlenecks in drug development pipeline
- Accelerate biotherapeutic discovery
- Process optimization for improved productivity
- Lack of structured data platform
- Data governance challenges
- Drug development pipeline challenges
- Scalability of high-throughput sequencing pipelines
- Industry-wide problems in drug development pipeline
- Rapid discovery of antibody therapeutic candidates
▲Active Projects
- High-throughput antibody screening
- Mid-scale cloning and expression operations
- Antibody discovery
- Lymph node organoid engineering
- Elisa-based immunoassay development
- Exis lymph node organoid platform
- Htp protein expression platform
- Cell line development workflows
- Automation of liquid handling workflows
- Oncology therapeutic area development
Hiring Activity
Department
Seniority
Notable leadership hires: Oncology Director, Business Development Director
